Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs CAVA Group Inc (CAVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs CAVA Group Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while CAVA Group Inc trades at $72.3 (market cap $8.41B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 4.7× CAVA Group Inc's market cap, and CAVA Group Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | CAVA | |
|---|---|---|
Market Cap | $39.89B | $8.41B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $97.39 |
52-Week Low | $278.09 | $43.59 |
Enterprise Value | $38.15B | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
CAVA Group trades at $72.18, up 5.84% in the last session, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported Q1 2026 EPS of $0.20, beating expectations, and revenue growth to $1.18 billion in 2025. Analyst sentiment remains strongly positive with 72% buy ratings and a consensus price target of $94.19, though high valuation multiples like a P/E of 138.81 signal premium pricing. Recent news highlights expansion and innovation efforts.
Outlook: CAVA's growth trajectory and analyst optimism support upside potential, but elevated valuations and margin pressures pose risks. Investment opportunity lies in continued expansion and market share gains, while risks include competitive intensity and execution challenges in scaling operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About CAVA Group Inc
CAVA is a Mediterranean fast-casual restaurant brand in the US. It offers customizable bowls, salads, and pitas featuring healthy ingredients, while also selling its signature dips and dressings in grocery stores.
Read more on CAVA →
